Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Stopped early · Phase 2

Conditions studied: Diffuse Large B Cell Lymphoma

In brief

Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. Panobinostat has shown effects against cancer in laboratory studies. However, it is not known if it will show the same activity in humans. Panobinostat has been given to participants with various types of cancers, including DLBCL, in previous research studies. In this study panobinostat will be given with the the antibody rituximab, which is FDA approved to be given with chemotherapy in DLBCL.

Key facts

Study ID

NCT01282476

Run by

Massachusetts General Hospital

People needed

18

Starts

2011-06-01

Expected to finish

2014-08-01

Last updated by the study team

2017-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or refractory DLBCL
• More than 1 line of prior chemotherapy

You may not qualify if…

• Currently receiving anticancer therapy or investigational agents
• Major surgery within last 4 weeks
• Known leptomeningeal or brain metastases
• Known HIV infection
• Uncontrolled fungal, bacterial, viral or other infection
• History of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 3 years
• Hepatitis B or C positive
• GI disease
• Pregnant or breastfeeding
• Prior treatment with an HDAC inhibitor including valproic acid

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.